Evaluating quality of life (QOL) in patients with idiopathic pulmonary fibrosis (IPF) goes beyond lung function numbers. It also shows how treatments affect daily well-being and guides funding, ...
Large genetic study links telomere-related polygenic risk to distinct idiopathic pulmonary fibrosis subgroups, improving disease prediction.
BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.
Hosted on MSN
Pulmonary fibrosis: Nerandomilast inhibits phosphodiesterase 4B, may treat multiple forms of disease
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...
CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...
In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results